UroGen Pharma Ltd Cash Flow-to-Debt Ratio
UroGen Pharma Ltd cash flow-to-debt ratio. UroGen Pharma Ltd (URGN) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2026, meaning its operating cash flow of $-33.01 Million could theoretically repay 0% of its total liabilities ($384.99 Million) in one year. Check URGN cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of UroGen Pharma Ltd (2013–2025)
Cash flow-to-debt ratio of UroGen Pharma Ltd from 2013 to 2025. Historical debt coverage capacity for UroGen Pharma Ltd across 13 annual periods. Check URGN total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
UroGen Pharma Ltd Cash Flow-to-Debt Ratio by Year (2013–2025)
UroGen Pharma Ltd cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for UroGen Pharma Ltd. For the full cash flow conversion analysis, see cash flow conversion of UroGen Pharma Ltd.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.53x | $-162.44 Million | $305.93 Million | ▼ -61.6% |
| 2024 | -0.33x | $-96.77 Million | $294.51 Million | ▼ -4.8% |
| 2023 | -0.31x | $-76.38 Million | $243.52 Million | ▲ +19.4% |
| 2022 | -0.39x | $-87.56 Million | $224.98 Million | ▲ +49.0% |
| 2021 | -0.76x | $-84.89 Million | $111.33 Million | ▲ +81.5% |
| 2020 | -4.13x | $-105.89 Million | $25.65 Million | ▼ -28.4% |
| 2019 | -3.22x | $-71.02 Million | $22.09 Million | ▼ -16.0% |
| 2018 | -2.77x | $-37.33 Million | $13.46 Million | ▼ -103.8% |
| 2017 | -1.36x | $-9.57 Million | $7.04 Million | ▼ -319.2% |
| 2016 | 0.62x | $4.19 Million | $6.75 Million | ▲ +119.4% |
| 2015 | -3.21x | $-7.17 Million | $2.24 Million | ▲ +30.6% |
| 2014 | -4.62x | $-4.12 Million | $891.00K | ▲ +12.5% |
| 2013 | -5.28x | $-2.56 Million | $484.00K | — |